Brain scan study hints at new way to tackle schizophrenia memory problems
NCT ID NCT04457310
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 39 times
Summary
This completed Phase 2 trial tested whether a drug called CVL-562 can change brain activity related to working memory in people with early schizophrenia. 112 participants received different doses or a placebo while undergoing brain scans. The goal was to find brain imaging markers that could help develop better treatments for cognitive issues in schizophrenia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University
New York, New York, 10032, United States
-
Stony Brook University
Stony Brook, New York, 11794, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Yale University
New Haven, Connecticut, 06511, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CVL-562 (PF-06412562)
What this could lead to
If successful, this study could help identify brain imaging markers that speed up development of new drugs for cognitive problems in schizophrenia.
What could go wrong
This is a small, early-phase study focused on measuring brain activity, not on proving the drug works. The results may not lead to a treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.